180 related articles for article (PubMed ID: 33517449)
21. Adult-onset leukoencephalopathy with vanishing white matter with compound heterozygous EIF2B3 gene variants.
Gui M; He M; Qin L
BMC Neurol; 2024 Jun; 24(1):201. PubMed ID: 38872124
[TBL] [Abstract][Full Text] [Related]
22. Case Report: A Novel
Wongkittichote P; Mar SS; McKinstry RC; Nguyen H
Front Genet; 2022; 13():893057. PubMed ID: 35783294
[TBL] [Abstract][Full Text] [Related]
23. Adult-onset vanishing white matter disease due to a novel EIF2B3 mutation.
La Piana R; Vanderver A; van der Knaap M; Roux L; Tampieri D; Brais B; Bernard G
Arch Neurol; 2012 Jun; 69(6):765-68. PubMed ID: 22312164
[TBL] [Abstract][Full Text] [Related]
24. Mutations causing childhood ataxia with central nervous system hypomyelination reduce eukaryotic initiation factor 2B complex formation and activity.
Richardson JP; Mohammad SS; Pavitt GD
Mol Cell Biol; 2004 Mar; 24(6):2352-63. PubMed ID: 14993275
[TBL] [Abstract][Full Text] [Related]
25. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
Pan YX; Wu Y; Niu ZP; Jiang YW
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
[TBL] [Abstract][Full Text] [Related]
26. Infantile onset Vanishing White Matter disease associated with a novel EIF2B5 variant, remarkably long life span, severe epilepsy, and hypopituitarism.
Woody AL; Hsieh DT; McIver HK; Thomas LP; Rohena L
Am J Med Genet A; 2015 Apr; 167A(4):826-30. PubMed ID: 25758335
[TBL] [Abstract][Full Text] [Related]
27. Biochemical effects of mutations in the gene encoding the alpha subunit of eukaryotic initiation factor (eIF) 2B associated with Vanishing White Matter disease.
Wortham NC; Proud CG
BMC Med Genet; 2015 Aug; 16():64. PubMed ID: 26285592
[TBL] [Abstract][Full Text] [Related]
28. Astrocytes are central in the pathomechanisms of vanishing white matter.
Dooves S; Bugiani M; Postma NL; Polder E; Land N; Horan ST; van Deijk AL; van de Kreeke A; Jacobs G; Vuong C; Klooster J; Kamermans M; Wortel J; Loos M; Wisse LE; Scheper GC; Abbink TE; Heine VM; van der Knaap MS
J Clin Invest; 2016 Apr; 126(4):1512-24. PubMed ID: 26974157
[TBL] [Abstract][Full Text] [Related]
29. A point mutation in translation initiation factor eIF2B leads to function--and time-specific changes in brain gene expression.
Marom L; Ulitsky I; Cabilly Y; Shamir R; Elroy-Stein O
PLoS One; 2011; 6(10):e26992. PubMed ID: 22073122
[TBL] [Abstract][Full Text] [Related]
30. Efficient detection of frequent eIF2B mutations for the rapid molecular diagnosis of CACH/VWM syndrome.
Ferreira MC; Dorboz I; Boespflug-Tanguy O
Clin Biochem; 2015 Dec; 48(18):1317-23. PubMed ID: 26162493
[TBL] [Abstract][Full Text] [Related]
31. Vanishing white matter disease with different faces.
Güngör G; Güngör O; Çakmaklı S; Maraş Genç H; İnce H; Yeşil G; Dilber C; Aydın K
Childs Nerv Syst; 2020 Feb; 36(2):353-361. PubMed ID: 31385086
[TBL] [Abstract][Full Text] [Related]
32. Leukoencephalopathy with vanishing white matter: a review.
Bugiani M; Boor I; Powers JM; Scheper GC; van der Knaap MS
J Neuropathol Exp Neurol; 2010 Oct; 69(10):987-96. PubMed ID: 20838246
[TBL] [Abstract][Full Text] [Related]
33. Ovarioleukodystrophy due to EIF2B5 mutations.
Ibitoye RT; Renowden SA; Faulkner HJ; Scolding NJ; Rice CM
Pract Neurol; 2016 Dec; 16(6):496-499. PubMed ID: 27651498
[TBL] [Abstract][Full Text] [Related]
34. An unmasked mutation of EIF2B2 due to submicroscopic deletion of 14q24.3 in a patient with vanishing white matter disease.
Shimada S; Miya K; Oda N; Watanabe Y; Kumada T; Sugawara M; Shimojima K; Yamamoto T
Am J Med Genet A; 2012 Jul; 158A(7):1771-7. PubMed ID: 22678813
[TBL] [Abstract][Full Text] [Related]
35. Vanishing white matter: deregulated integrated stress response as therapy target.
Abbink TEM; Wisse LE; Jaku E; Thiecke MJ; Voltolini-González D; Fritsen H; Bobeldijk S; Ter Braak TJ; Polder E; Postma NL; Bugiani M; Struijs EA; Verheijen M; Straat N; van der Sluis S; Thomas AAM; Molenaar D; van der Knaap MS
Ann Clin Transl Neurol; 2019 Aug; 6(8):1407-1422. PubMed ID: 31402619
[TBL] [Abstract][Full Text] [Related]
36. Adult-onset leukodystrophy with vanishing white matter: a case series of 19 patients.
Benzoni C; Moscatelli M; Farina L; Magri S; Ciano C; Scaioli V; Alverà S; Cammarata G; Bianchi-Marzoli S; Castellani M; Zito FM; Marotta G; Piacentini S; Villacara A; Mantegazza R; Gellera C; Durães J; Gouveia A; Matos A; do Carmo Macário M; Pareyson D; Taroni F; Di Bella D; Salsano E
J Neurol; 2023 Sep; 270(9):4219-4234. PubMed ID: 37171481
[TBL] [Abstract][Full Text] [Related]
37. Poor cerebral inflammatory response in eIF2B knock-in mice: implications for the aetiology of vanishing white matter disease.
Cabilly Y; Barbi M; Geva M; Marom L; Chetrit D; Ehrlich M; Elroy-Stein O
PLoS One; 2012; 7(10):e46715. PubMed ID: 23056417
[TBL] [Abstract][Full Text] [Related]
38. Vanishing white matter disease in French-Canadian patients from Quebec.
Robinson MÈ; Rossignol E; Brais B; Rouleau G; Arbour JF; Bernard G
Pediatr Neurol; 2014 Aug; 51(2):225-32. PubMed ID: 25079571
[TBL] [Abstract][Full Text] [Related]
39. Vanishing white matter: Eukaryotic initiation factor 2B model and the impact of missense mutations.
Slynko I; Nguyen S; Hamilton EMC; Wisse LE; de Esch IJP; de Graaf C; Bruning JB; Proud CG; Abbink TEM; van der Knaap MS
Mol Genet Genomic Med; 2021 Mar; 9(3):e1593. PubMed ID: 33432707
[TBL] [Abstract][Full Text] [Related]
40. A novel missense variant in
Nourmohammadi P; Asadollahi M; Karamzade A; Eshaghkhani Y; Babaei M; Golchehre Z; Taheri SR; Hasani S; Taghizadeh M; Keramatipour M
J Genet; 2023; 102():. PubMed ID: 37674283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
